Edition:
United States

Abbott Laboratories (ABT)

ABT on New York Consolidated

55.62USD
18 Oct 2017
Change (% chg)

$0.56 (+1.01%)
Prev Close
$55.06
Open
$55.18
Day's High
$56.60
Day's Low
$54.92
Volume
3,192,911
Avg. Vol
5,715,859
52-wk High
$56.60
52-wk Low
$37.38

Latest Key Developments (Source: Significant Developments)

Abbott Q3 adjusted EPS $0.66 from continuing operations
7:45am EDT 

Oct 18 (Reuters) - Abbott Laboratories ::Abbott reports third-quarter 2017 results.Sees FY 2017 gaap earnings per share $0.97 to $0.99 from continuing operations.Q3 adjusted earnings per share $0.66 from continuing operations.Q3 gaap earnings per share $0.32 from continuing operations.Q3 earnings per share view $0.65 -- Thomson Reuters I/B/E/S.Sees Q4 adjusted earnings per share $0.72 to $0.74 from continuing operations excluding items.Sees FY 2017 adjusted earnings per share $2.48 to $2.50 from continuing operations.Sees Q4 2017 gaap earnings per share $0.28 to $0.30 from continuing operations.Q3 sales $6.8 billion versus I/B/E/S view $6.72 billion.Abbott Laboratories - ‍narrowed its full-year 2017 eps guidance range​.Abbott Laboratories qtrly total pediatric sales $‍975​ million, up 0.8 percent on a reported basis.Abbott Laboratories qtrly total nutrition sales $1,768 million, up 0.8 percent on a reported basis‍​.Abbott Laboratories - qtrly total vascular sales $‍724​ million, up 17.1 percent on reported basis.Abbott Laboratories - qtrly total diagnostics sales $1,279 million, up 5.4 percent on a reported basis ‍​.Abbott Laboratories - ‍on Oct. 3, 2017, Abbott completed acquisition of Alere​.FY 2017 earnings per share view $2.50 -- Thomson Reuters I/B/E/S.Q4 earnings per share view $0.74 -- Thomson Reuters I/B/E/S.Abbott Laboratories - ‍expects to initiate launch of its alinity systems in U.S. In 2018​.  Full Article

Abbott Laboratories says ‍announced U.S. Launch of company's proclaim DRG neurostimulator system​
Monday, 16 Oct 2017 09:00am EDT 

Oct 16 (Reuters) - Abbott Laboratories ::Abbott laboratories - ‍announced U.S. launch of company's proclaim DRG neurostimulator system​.  Full Article

Abbott completes cash tender offer for Series B Convertible Perpetual Preferred Stock of Alere Inc
Wednesday, 4 Oct 2017 08:00am EDT 

Oct 4 (Reuters) - Abbott Laboratories :Abbott completes cash tender offer for Series B Convertible Perpetual Preferred Stock of Alere Inc..  Full Article

Abbott extends previous cash tender offer for outstanding Series B shares of Alere Inc
Monday, 2 Oct 2017 08:00am EDT 

Oct 2 (Reuters) - Abbott Laboratories :Abbott announces extension of cash tender offer for all outstanding shares of Series B convertible perpetual preferred stock of Alere Inc..Abbott Laboratories - offer to purchase all shares of Series B preferred stock of Alere will now expire at 11:59 p.m. New York City time on Tuesday, Oct. 3, 2017.  Full Article

Abbott secures FDA approval for MRI-compatibility for the co's Ellipse ICD
Friday, 22 Sep 2017 08:00am EDT 

Sept 22 (Reuters) - Abbott Laboratories :Abbott secures FDA approval for MRI-compatibility for the company's Ellipse ICD.  Full Article

Abbott announces extension of cash tender offer
Monday, 18 Sep 2017 08:01am EDT 

Sept 18 (Reuters) - Abbott Laboratories :Abbott announces extension of cash tender offer for all outstanding shares of series B convertible perpetual preferred stock of Alere Inc..Abbott Laboratories - ‍ offer will now expire at 11:59 p.m., New York City time, on Friday, Sept. 29, 2017​.  Full Article

Quidel announces revised agreement for pending acquisition of Alere’s business
Monday, 18 Sep 2017 07:00am EDT 

Sept 18 (Reuters) - Quidel Corp :Quidel announces revised agreement for its pending acquisition of Alere’s B-type Naturietic Peptide (BNP) assay business run on Beckman Coulter Analyzers.Quidel - ‍ previously announced transaction to purchase Triage Meterpro cardiovascular and toxicology assets from alere remains substantially unchanged​.Quidel-‍revised agreement provides co direct commercial responsibility after purchase for all sales globally of Alere's BNP assay unit run on Beckman Analyzers​.Quidel Corp - ‍ transactions will be funded through a combination of cash on hand and committed financing​.Quidel Corp - ‍total cash consideration for Alere's Triage MeterPro assets and beckman coulter bnp sales​ will now be up to $680 million.Quidel Corp - ‍ believe co is on track to close acquisition of Triage and BNP businesses within 30 days of Abbott's close of Alere acquisition​.Quidel- deal consideration of $680 million made of $400 million purchase price for triage business, $40 million in contingent consideration for eea bnp business.Quidel- deal consideration of $680 million also comprised of $240 million in deferred consideration for rest-of-world BNP business​.  Full Article

Abbott sets quarterly dividend of $0.265 per share
Thursday, 14 Sep 2017 12:30pm EDT 

Sept 14 (Reuters) - Abbott ::Sets quarterly dividend of $0.265 per share.  Full Article

Abbott Laboratories says ‍NHS Business Services Authority approved listing on Drug Tariff for FreeStyle Libre system
Wednesday, 13 Sep 2017 07:01am EDT 

Sept 13 (Reuters) - Abbott Laboratories :Abbott Laboratories - ‍NHS Business Services Authority approved listing on Drug Tariff for FreeStyle Libre system for people with diabetes using insulin​.Abbott Laboratories - ‍ from Nov. 1, 2017 FreeStyle Libre flash glucose monitoring technology will be available for reimbursement via NHS ​.  Full Article

Abbott initiates study of AMPLATZER device to correct congenital heart defect in newborns
Wednesday, 30 Aug 2017 11:56am EDT 

Aug 30 (Reuters) - Abbott Laboratories :Abbott initiates ground-breaking U.S. pivotal study of AMPLATZER device to correct common congenital heart defect in newborns.‍Study of AMPLATZER device​ will enroll approximately 50 patients at up to 10 centers across United States.  Full Article

Photo

Abbott beats Street on strong medical device, generics sales

Abbott Laboratories' profit and sales topped analysts' estimates on robust sales of medical devices and generic drugs, leading it to raise the high-end of its adjusted earnings forecast for the year.